Company intelligence / Profile preview

Adalid Sciences

Prague, Czech Republicadalidsciences.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Adalid Sciences is developing structurally novel, safe, and effective lipid nanoparticles to improve the stability, bioavailability, and targeted delivery of RNA/DNA therapeutics. Their LNPs have demonstrated promising safety and efficacy in preclinical models. The company is currently focused on validating its platform through further preclinical work and collaborations with biotech/pharma partners.

Therapeutic areas: OtherRare Diseases
Modalities: Lipid nanoparticles (LNPs)Nucleic acid-based therapeutics (RNA, DNA)
Industry: Drug Discovery Services

Partnerships

IOCB Tech/Institute of Organic Chemistry & Biochemistry Prague (technology transfer/support)BTL Group investment partnershipseeking collaborations with pharma/biotech companies developing nucleic acid therapies

Beyond the preview

Go deeper on Adalid Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adalid Sciences.

Explore the full profile